Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy

被引:25
作者
Bianco, FJ [1 ]
Wood, DP
Grignon, DJ
Sakr, WA
Pontes, JE
Powell, IJ
机构
[1] Wayne State Univ, Sch Med, Dept Urol, Detroit, MI 48202 USA
[2] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48202 USA
[3] Barbara Ann Karmanos Canc Inst, Prostate Program, Detroit, MI USA
关键词
prostate; prostatic neoplasms; blacks; whites; disease-free survival;
D O I
10.1016/S0022-5347(05)64662-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The initiation of prostate specific antigen (PSA) testing has led to increased public awareness, early detection and a stage shift in prostate cancer. We have previously reported that black American men have worse disease-free survival independently of pathological or clinical factors. We tested the stage shift effects on disease-free survival in our cohort of patients treated with radical prostatectomy. Materials and Methods: A total of 1,042 consecutive patients underwent radical prostatectomy performed by Wayne State University full-time faculty. The cohort was divided by the year of surgery as before (585 men in group 1) or after (457 in group 2) 1996. Clinicopathological and disease-free survival data were obtained from the Karmanos Cancer Institute multidisciplinary prostate cancer database. Results: Improvements in clinical stage, preoperative PSA and biopsy Gleason score were observed in group 2 (p = 0.0001). Pathological organ confined disease increased in group 2 versus 1 in the 2 races, including 89 of 153 (58%) from 66 of 178 (37%) in black men and 189 of 304 (62%) from 194 of 407 (48%) in white men (p = 0.003 and 0.001, respectively). Calculated cancer recurrence-free median probability in group 1 at 42 months was 81% and 68% in white and black men, respectively (log rank test p = 0.001). These differences became insignificant in group 2 patients at 42 months with a median probability of 90% and 88% in white and black men, respectively (log rank test p = 0.39), representing a net increase in disease-free survival of 20% in black men. Specimen Gleason score, PSA and pathological stage were independent predictors of survival in the 2 groups. In contrast, race was an independent predictor only in group 1. Conclusions: The increased rate of pathological organ confined disease is translating into improved disease-free survival rates. These early data suggest that the survival gap in black and white American men is narrowing and may become statistically insignificant.
引用
收藏
页码:479 / 482
页数:4
相关论文
共 26 条
  • [1] Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued rise of biochemical failure after 5 years
    Amling, CL
    Blute, ML
    Bergstralh, EJ
    Seay, TM
    Slezak, J
    Zincke, H
    [J]. JOURNAL OF UROLOGY, 2000, 164 (01) : 101 - 105
  • [2] [Anonymous], NIH PUBLICATION
  • [3] Bianco Fernando J., 2001, Journal of Urology, V165, P330
  • [4] Lowering PSA cutoffs to enhance detection of curable prostate cancer
    Catalona, WJ
    Ramos, CG
    Carvalhal, GF
    Yan, Y
    [J]. UROLOGY, 2000, 55 (06) : 791 - 795
  • [5] Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination - Enhancement of specificity with free PSA measurements
    Catalona, WJ
    Smith, DS
    Ornstein, DK
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18): : 1452 - 1455
  • [6] Cancer statistics, 2001
    Greenlee, RT
    Hill-Harmon, MB
    Murray, T
    Thun, M
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2001, 51 (01) : 15 - 36
  • [7] Grignon DJ, 1996, CANCER-AM CANCER SOC, V78, P337, DOI 10.1002/(SICI)1097-0142(19960715)78:2<337::AID-CNCR23>3.0.CO
  • [8] 2-W
  • [9] Cancer surveillance series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
    Hankey, BF
    Feuer, EJ
    Clegg, LX
    Hayes, RB
    Legler, JM
    Prorok, PC
    Ries, LA
    Merrill, RM
    Kaplan, RS
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (12): : 1017 - 1024
  • [10] RETRACTED: Prostate cancer screening in the Tyrol, Austria: experience and results (Retracted article. See vol. 48, pg. 286, 2012)
    Horninger, W
    Reissigl, A
    Rogatsch, H
    Volgger, H
    Studen, M
    Klocker, H
    Bartsch, G
    [J]. EUROPEAN JOURNAL OF CANCER, 2000, 36 (10) : 1322 - 1335